Montara Therapeutics develops therapies for neurological diseases by leveraging its proprietary BrainOnly™ platform to enhance drug safety and efficacy. This platform utilizes Brain-Targeting Chimeras (BrainTAC™) to concentrate pharmacological activity in the brain while preventing peripheral toxicities. The technology aims to enable the drugging of established targets and improve the therapeutic index for neurodegenerative conditions and brain cancer.
Funding
$8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DDFounders
Product
Problem
Many drug candidates for neurological diseases fail due to dose-limiting peripheral toxicities, hindering both safety and efficacy. This challenge limits the ability to effectively target previously undruggable neurological targets.
Solution
Montara Therapeutics is developing BrainOnly™, a platform designed to concentrate drug activity in the brain while minimizing peripheral toxicities. This approach aims to improve the therapeutic index and enable the development of safer, more effective therapies for neurological diseases. The BrainOnly™ platform can be utilized with novel or existing small molecule inhibitors or activators to enhance the profile of existing drugs and access many currently undruggable targets. The platform holds the potential to deliver a new generation of brain-targeted therapeutics with broad applicability across neurological diseases, including neurodegenerative diseases and brain cancer.
Target Audience
The primary target audience includes pharmaceutical companies and researchers focused on developing therapies for neurological diseases, particularly those seeking to improve drug safety and efficacy while targeting previously undruggable targets.
Features
- Prevents peripheral adverse events associated with neuroscience drugs.
- Enhances drug safety and efficacy through targeted drug delivery to the brain.
- Compatible with both novel and existing small molecule inhibitors or activators.
- Applicable across a range of neurological diseases, including neurodegenerative disorders and brain cancer.